Recent News

Arialys Therapeutics Initiates MAD Cohorts Having Completed All Planned SAD Cohorts in a Phase 1 Study of ART5803 for the Treatment of Autoimmune Neuropsychiatric Disease

Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC

Valora Therapeutics Raises $30 Million Seed Financing

Enlaza Therapeutics marries covalent and biologic drugs

Arialys Therapeutics Announces First Participants Dosed in a Phase 1 Clinical Trial of ART5803, a Precision Medicine for the Treatment of Autoimmune Neuropsychiatric Diseases

A Biotech Dousing ‘Fires’ in the Brain that Plagued a Bestselling Author

Otsuka Pharmaceutical to Acquire Jnana Therapeutics

Boehringer Ingelheim secures novel immune checkpoint inhibitor with acquisition of Nerio Therapeutics

FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)